EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Erythropoiesis-stimulating agent resistance is associated with diabetic kidney disease but not with diabetes: a post hoc analysis of the BRIGHTEN study

Ryousuke Aoki, Keiichi Matsuzaki, Hitoshi Suzuki, Tatsuo Kagimura, Tadashi Sofue, Takashi Wada, Ichiei Narita, Yusuke Suzuki

Clinical and Experimental Nephrology · 2026-08 · 30 (8) · 1196-1207

DOI: 10.1007/s10157-026-02881-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Nephrology, online erschienen am 18.05.2026. Verfasst von Ryousuke Aoki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Hematinics, Drug Resistance, Anemia. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Erythropoiesis-stimulating agent (ESA) resistance in chronic kidney disease (CKD) is influenced by various factors, including diabetes. Although diabetes has been linked to ESA resistance, the BRIGHTEN study in Japan found no direct correlation. This study aimed to identify factors contributing to ESA resistance in patients with diabetes by analyzing the diabetic kidney disease (DKD) status and CKD stage.

Methods

A post hoc analysis was conducted using data from the BRIGHTEN study, a multicenter prospective observational trial investigating ESA resistance in patients with non-dialysis-dependent CKD. Patients were categorized based on diabetes status (DM vs. non-DM) and further stratified by CKD stage and presence of DKD. ESA resistance was assessed using the erythropoietin resistance index.

Results

No significant differences in ESA resistance were observed between the DM and non-DM groups. However, among patients with diabetes, those with DKD exhibited higher ESA resistance and required higher darbepoetin alfa (DA) dosages than did those with non-DKD nephropathy (NDKD-DM). ESA resistance and DA dosage increased with CKD progression, with notable differences in CKD stage G4 between the DKD and NDKD-DM groups.

Conclusion

Although diabetes alone was not associated with ESA resistance, patients with DKD exhibited higher resistance, suggesting that ESA resistance is more closely linked to DKD than to diabetes itself. These findings highlight the role of proteinuria and inflammation in the ESA response, emphasizing the need for individualized anemia management strategies based on nephropathy type.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesHematinicsDrug ResistanceAnemiaDarbepoetin alfaRenal Insufficiency, ChronicHumansFemaleMaleAgedMiddle AgedProspective StudiesDisease ProgressionJapan

Stichwörter der Autor:innen

Diabetic kidney diseaseProteinuriaRenal anemia

Substanzen

HematinicsDarbepoetin alfa

Autor:innen und Institutionen

  • Department of Nephrology, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
  • Department of Public Health, Kitasato University School of Medicine, Kanagawa, Japan.
  • Department of Nephrology, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. shitoshi@juntendo.ac.jp.
  • Department of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan. shitoshi@juntendo.ac.jp.
  • Translational Research Center for Medical Innovation , Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan.
  • Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine , Kagawa University, Takamatsu, Japan.

Zitieren

APA

Aoki, R., Matsuzaki, K., Suzuki, H., Kagimura, T., Sofue, T., Wada, T., Narita, I., & Suzuki, Y. (2026). Erythropoiesis-stimulating agent resistance is associated with diabetic kidney disease but not with diabetes: a post hoc analysis of the BRIGHTEN study. Clinical and Experimental Nephrology, 30(8), 1196-1207. https://doi.org/10.1007/s10157-026-02881-2

Vancouver

Aoki R, Matsuzaki K, Suzuki H, Kagimura T, Sofue T, Wada T, et al. Erythropoiesis-stimulating agent resistance is associated with diabetic kidney disease but not with diabetes: a post hoc analysis of the BRIGHTEN study. Clinical and Experimental Nephrology. 2026;30(8):1196-1207. doi:10.1007/s10157-026-02881-2

BibTeX
@article{Aoki2026,
  author = {Aoki, Ryousuke and Matsuzaki, Keiichi and Suzuki, Hitoshi and Kagimura, Tatsuo and Sofue, Tadashi and Wada, Takashi and Narita, Ichiei and Suzuki, Yusuke},
  title = {Erythropoiesis-stimulating agent resistance is associated with diabetic kidney disease but not with diabetes: a post hoc analysis of the BRIGHTEN study},
  journal = {Clinical and Experimental Nephrology},
  year = {2026},
  volume = {30},
  number = {8},
  pages = {1196--1207},
  doi = {10.1007/s10157-026-02881-2}
}
Kostenlos starten →